| Merkel cell carcinoma

Zynyz vs Keytruda

Side-by-side clinical, coverage, and cost comparison for merkel cell carcinoma.

Deep comparison between: Zynyz vs Keytruda with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsKeytruda has a higher rate of injection site reactions vs Zynyz based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Keytruda but not Zynyz, including UnitedHealthcare

Category

Zynyz

Keytruda

At A Glance

RouteIntravenous infusion

FrequencyEvery 3 or 4 weeks

ClassPD-1 blocking antibody

RouteIV infusion

FrequencyEvery 3 weeks or Every 6 weeks

ClassPD-1 inhibitor

Indications

Primary squamous cell carcinoma of anal canal
Merkel cell carcinoma

melanoma
Non-Small Cell Lung Carcinoma
Malignant Pleural Mesothelioma
Squamous cell carcinoma of the head and neck
Classic Hodgkin Lymphoma
Mediastinal (Thymic) Large B-Cell Lymphoma
Urothelial Carcinoma
Colorectal Carcinoma
Stomach Carcinoma
Esophageal carcinoma
Cervix carcinoma
Liver carcinoma
Biliary Tract Cancer
Merkel cell carcinoma
Renal Cell Carcinoma
Endometrial Carcinoma
Triple-Negative Breast Carcinoma
Malignant neoplasm of ovary
Squamous cell carcinoma of skin

Dosing

Primary squamous cell carcinoma of anal canal (Combination therapy) 500 mg every 4 weeks or 375 mg every 3 weeks in combination with carboplatin and paclitaxel until disease progression, unacceptable toxicity, or up to 12 months

Primary squamous cell carcinoma of anal canal (Monotherapy, platinum-refractory) 500 mg every 4 weeks or 375 mg every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months

Merkel cell carcinoma 500 mg every 4 weeks until disease progression, unacceptable toxicity, or up to 24 months

melanoma 200 mg every 3 weeks or 400 mg every 6 weeks IV; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics

Non-Small Cell Lung Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Malignant Pleural Mesothelioma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Squamous cell carcinoma of the head and neck 200 mg every 3 weeks or 400 mg every 6 weeks IV

Classic Hodgkin Lymphoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics

Mediastinal (Thymic) Large B-Cell Lymphoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics

Urothelial Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Colorectal Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics

Stomach Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Esophageal carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Cervix carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Liver carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Biliary Tract Cancer 200 mg every 3 weeks or 400 mg every 6 weeks IV

Merkel cell carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV for adults; 2 mg/kg (up to 200 mg) every 3 weeks IV for pediatrics

Renal Cell Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV as single agent or in combination with axitinib 5 mg orally twice daily or lenvatinib 20 mg orally once daily

Endometrial Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV in combination with carboplatin and paclitaxel, or with lenvatinib 20 mg orally once daily, or as single agent for MSI-H or dMMR tumors

Triple-Negative Breast Carcinoma 200 mg every 3 weeks or 400 mg every 6 weeks IV

Malignant neoplasm of ovary 200 mg every 3 weeks or 400 mg every 6 weeks IV

Squamous cell carcinoma of skin 200 mg every 3 weeks or 400 mg every 6 weeks IV

Contraindications

—

Drug Interactions

26View drug interactions

189View drug interactions

Adverse Reactions

Most common (>=10%) with combination therapy Fatigue, peripheral neuropathy, nausea, alopecia, diarrhea, musculoskeletal pain, constipation, hemorrhage, rash, vomiting, decreased appetite, pruritus, abdominal pain

Most common (>=10%) with SCAC monotherapy Fatigue, musculoskeletal pain, diarrhea, non-urinary tract infections, perineal pain, hemorrhage, urinary tract infection, rash, nausea, decreased appetite, constipation, abdominal pain, dyspnea, pyrexia, vomiting, cough, pruritus, hypothyroidism, headache, decreased weight

Most common (>=10%) in MCC Musculoskeletal pain, fatigue, pruritus, diarrhea, rash, pyrexia, nausea, constipation

Serious Sepsis, pulmonary embolism, diarrhea, vomiting, non-urinary tract infection, perineal pain, anemia, hemorrhage, arrhythmia, pneumonitis, immune-mediated adverse reactions

Most common (>=20%) fatigue, musculoskeletal pain, decreased appetite, rash, diarrhea, nausea, cough, dyspnea, constipation, pruritus, hypothyroidism

Serious pneumonitis, colitis, hepatitis, endocrinopathies, nephritis with renal dysfunction, dermatologic adverse reactions, myocarditis, neurological toxicities, infusion-related reactions, immune-mediated adverse reactions

Postmarketing exocrine pancreatic insufficiency, sclerosing cholangitis

Pharmacology

Retifanlimab-dlwr is a PD-1 blocking antibody that binds to the PD-1 receptor, blocks interaction with its ligands PD-L1 and PD-L2, and potentiates T-cell activity to restore immune surveillance of tumors.

Pembrolizumab is a PD-1 blocking antibody that releases PD-1 pathway-mediated inhibition of the immune response by preventing the interaction of PD-1 with its ligands PD-L1 and PD-L2, thereby restoring anti-tumor immune response.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Zynyz